|
1
|
Conter HJ, Gopalakrishnan V, Ravi V, Ater JL, Patel S and Araujo DM: Adult versus pediatric neuroblastoma: The M.D. Anderson Cancer Center experience. Sarcoma. 2014:3751512014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barbieri E, De Preter K, Capasso M, Johansson P, Man TK, Chen Z, Stowers P, Tonini GP, Speleman F and Shohet JM: A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma. PLoS One. 8:e798432013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lerone M, Ognibene M, Pezzolo A, Martucciello G, Zara F, Morini M and Mazzocco K: Molecular genetics in neuroblastoma prognosis. Children (Basel). 8:4562021.PubMed/NCBI
|
|
4
|
Smith V and Foster J: High-risk neuroblastoma treatment review. Children (Basel). 5:1142018.PubMed/NCBI
|
|
5
|
Donghi R, Longoni A, Pilotti S, Michieli P, Porta GD and Pierotti MA: Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest. 91:1753–1760. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ago K, Shibutani M, Saegusa Y, Shima T, Taniai E and Mitsumori K: A case report of a cerebellar neuroblastoma in a p53 null mutation mouse. J Vet Med Sci. 71:345–347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bu X, Shen Z and Jin B: Expression of p53 in nephroblastoma and neuroblastoma. Zhonghua Wai Ke Za Zhi. 35:220–222. 1997.(In Chinese). PubMed/NCBI
|
|
8
|
Feng Z, Zhang H, Levine AJ and Jin S: The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA. 102:8204–8209. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu X, Harris SL and Levine AJ: The regulation of exosome secretion: A novel function of the p53 protein. Cancer Res. 66:4795–4801. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, de Graaf P, Francoz S, Gasparini P, Gobbi A, et al: Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol. 24:5835–5843. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oliner JD, Saiki AY and Caenepeel S: The role of MDM2 amplification and overexpression in tumorigenesis. Cold Spring Harb Perspect Med. 6:a0263362016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gamble LD, Kees UR, Tweddle DA and Lunec J: MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Oncogene. 31:752–763. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nicolai S, Pieraccioli M, Peschiaroli A, Melino G and Raschella G: Neuroblastoma: Oncogenic mechanisms and therapeutic exploitation of necroptosis. Cell Death Dis. 6:e20102015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Isaacs JS, Saito S and Neckers LM: Requirement for HDM2 activity in the rapid degradation of p53 in neuroblastoma. J Biol Chem. 276:18497–18506. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Inomistova MV, Svergun NM, Khranovska NM, Skachkova OV, Gorbach OI and Klymnyuk GI: Prognostic significance of MDM2 gene expression in childhood neuroblastoma. Exp Oncol. 37:111–115. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fan YH, Cheng J, Vasudevan SA, Dou J, Zhang H, Patel RH, Ma IT, Rojas Y, Zhao Y, Yu Y, et al: USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis. 4:e8672013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheng J, Fan YH, Xu X, Zhang H, Dou J, Tang Y, Zhong X, Rojas Y, Yu Y, Zhao Y, et al: A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell Death Dis. 5:e10792014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vogan K, Bernstein M, Leclerc JM, Brisson L, Brossard J, Brodeur GM, Pelletier J and Gros P: Absence of p53 gene mutations in primary neuroblastomas. Cancer Res. 53:5269–5273. 1993.PubMed/NCBI
|
|
19
|
Diskin SJ, Capasso M, Diamond M, Oldridge DA, Conkrite K, Bosse KR, Russell MR, Iolascon A, Hakonarson H, Devoto M and Maris JM: Rare variants in TP53 and susceptibility to neuroblastoma. J Natl Cancer Inst. 106:dju0472014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Imamura J, Bartram CR, Berthold F, Harms D, Nakamura H and Koeffler HP: Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res. 53:4053–4058. 1993.PubMed/NCBI
|
|
21
|
Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, et al: Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA. 105:3933–3938. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Canner JA, Sobo M, Ball S, Hutzen B, DeAngelis S, Willis W, Studebaker AW, Ding K, Wang S, Yang D and Lin J: MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br J Cancer. 101:774–781. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang S, Sun W, Zhao Y, McEachern D, Meaux I, Barrière C, Stuckey JA, Meagher JL, Bai L, Liu L, et al: SAR405838: An optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 74:5855–5865. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bill KL, Garnett J, Meaux I, Ma X, Creighton CJ, Bolshakov S, Barriere C, Debussche L, Lazar AJ, Prudner BC, et al: SAR405838: A novel and potent inhibitor of the MDM2:p53 axis for the treatment of dedifferentiated liposarcoma. Clin Cancer Res. 22:1150–1160. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chessari G, Hardcastle IR, Ahn JS, Anil B, Anscombe E, Bawn RH, Bevan LD, Blackburn TJ, Buck I, Cano C, et al: Structure-based design of potent and orally active isoindolinone inhibitors of MDM2-p53 protein-protein interaction. J Med Chem. 64:4071–4088. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Burmakin M, Shi Y, Hedström E, Kogner P and Selivanova G: Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res. 19:5092–5103. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tesson M, Vasan R, Hock A, Nixon C, Rae C, Gaze M and Mairs R: An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma. Oncotarget. 9:29082–29096. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen L, Rousseau RF, Middleton SA, Nichols GL, Newell DR, Lunec J and Tweddle DA: Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget. 6:10207–10221. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell K, et al: Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Sci Transl Med. 10:eaao30032018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fang DD, Tang Q, Kong Y, Rong T, Wang Q, Li N, Fang X, Gu J, Xiong D, Yin Y, et al: MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models. Cell Death Discov. 7:902021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ding K, Lu Y, Nikolovska-Coleska Z, Wang G, Qiu S, Shangary S, Gao W, Qin D, Stuckey J, Krajewski K, et al: Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem. 49:3432–3435. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aziz MH, Shen H and Maki CG: Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene. 30:4678–4686. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Löschmann N, Voges Y, Breitling R, von Deimling A, Rödel F, et al: Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis. 2:e2432011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lu J, Guan S, Zhao Y, Yu Y, Wang Y, Shi Y, Mao X, Yang KL, Sun W, Xu X, et al: Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma. Oncotarget. 7:82757–82769. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li Z, Li X, Xu L, Tao Y, Yang C, Chen X, Fang F, Wu Y, Ding X, Zhao H, et al: Inhibition of neuroblastoma proliferation by PF-3758309, a small-molecule inhibitor that targets p21-activated kinase 4. Oncol Rep. 38:2705–2716. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu G, Wang LG, Han Y and He QY: ClusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li ZH, Du WW, Xu LX, Zhao H, Li XL, Fang F, Wu Y, Lu J, Li YH, Du WW, et al: A novel sphingosine kinase 1 inhibitor (SKI-5C) induces cell death of Wilms' tumor cells in vitro and in vivo. Am J Transl Res. 8:4548–4563. 2016.PubMed/NCBI
|
|
38
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Morales La Madrid A, Campbell N, Smith S, Cohn SL and Salgia R: Targeting ALK: A promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol. 7:199–210. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee H, Ren J, Pesavento RP, Ojeda I, Rice AJ, Lv H, Kwon Y and Johnson ME: Identification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling. Bioorg Med Chem. 27:1981–1989. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen C and Lan MS: A promoter-driven assay for INSM1-associated signaling pathway in neuroblastoma. Cell Signal. 76:1097852020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pieters R, Schrappe M, De Lorenzo P, Hann I, Rossi GD, Felice M, Hovi L, LeBlanc T, Szczepanski T, Ferster A, et al: A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): An observational study and a multicentre randomised trial. Lancet. 370:240–250. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Timmerman DM, Remmers TL, Hillenius S and Looijenga LHJ: Mechanisms of TP53 pathway inactivation in embryonic and somatic cells-relevance for understanding (Germ Cell) tumorigenesis. Int J Mol Sci. 22:53772021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rivlin N, Brosh R, Oren M and Rotter V: Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis. Genes Cancer. 2:466–474. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Martin-Caballero J, Flores JM, Garcia-Palencia P and Serrano M: Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res. 61:6234–6238. 2001.PubMed/NCBI
|
|
46
|
Zhang Y, Xiong Y and Yarbrough GW: ARF Promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 92:725–734. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu J, Zhang C, Wang XL, Ly P, Belyi V, Xu-Monette ZY, Young KH, Hu W and Feng Z: E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis. Cell Death Differ. 21:1792–1804. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Moll UM and Petrenko O: The MDM2-p53 interaction. Mol Cancer Res. 1:1001–1008. 2003.PubMed/NCBI
|
|
49
|
Tweddle DA, Pearson ADJ, Haber M, Norris MD, Xue C, Flemming C and Lunec J: The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 197:93–98. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Goldschneider D, Horvilleur E, Plassa LF, Guillaud-Bataille M, Million K, Wittmer-Dupret E, Danglot G, de Thé H, Bénard J, May E and Douc-Rasy S: Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res. 34:5603–5612. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wolter J, Angelini P and Irwin M: p53 family: Therapeutic targets in neuroblastoma. Future Oncol. 6:429–444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhao Y, Liu L, Sun W, Lu J, McEachern D, Li X, Yu S, Bernard D, Ochsenbein P, Ferey V, et al: Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors. J Am Chem Soc. 135:7223–7234. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Van Maerken T, Vandesompele J, Rihani A, De Paepe A and Speleman F: Escape from p53-mediated tumor surveillance in neuroblastoma: Switching off the p14(ARF)-MDM2-p53 axis. Cell Death Differ. 16:1563–1572. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Nor F, Warner KA, Zhang Z, Acasigua GA, Pearson AT, Kerk SA, Helman JI, Filho MS, Wang S and Nör JE: Therapeutic inhibition of the MDM2-p53 interaction prevents recurrence of adenoid cystic carcinomas. Clin Cancer Res. 23:1036–1048. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Andrews A, Warner K, Rodriguez-Ramirez C, Pearson AT, Nör F, Zhang Z, Kerk S, Kulkarni A, Helman JI, Brenner JC, et al: Ablation of cancer stem cells by therapeutic inhibition of the MDM2-p53 interaction in mucoepidermoid carcinoma. Clin Cancer Res. 25:1588–1600. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
de Jonge M, de Weger VA, Dickson MA, Langenberg M, Cesne AL, Wagner AJ, Hsu K, Zheng W, Macé S, Tuffal G, et al: A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. Eur J Cancer. 76:144–151. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mahalakshmi B, Baskaran R, Shanmugavadivu M, Nguyen NT and Velmurugan BK: Insulinoma-associated protein 1 (INSM1): A potential biomarker and therapeutic target for neuroendocrine tumors. Cell Oncol (Dordr). 43:367–376. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sanz G, Singh M, Peuget S and Selivanova G: Inhibition of p53 inhibitors: Progress, challenges and perspectives. J Mol Cell Biol. 11:586–599. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Breslin MB, Zhu M, Notkins AL and Lan MS: Neuroendocrine differentiation factor, IA-1, is a transcriptional repressor and contains a specific DNA-binding domain: Identification of consensus IA-1 binding sequence. Nucleic Acids Res. 30:1038–1045. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chen C, Breslin MB and Lan MS: INSM1 increases N-myc stability and oncogenesis via a positive-feedback loop in neuroblastoma. Oncotarget. 6:36700–36712. 2015. View Article : Google Scholar : PubMed/NCBI
|
